Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Applied Health Economics and Health Policy
Erschienen in: Applied Health Economics and Health Policy 5/2013

01.10.2013 | Original Research Article

Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany

verfasst von: Jan Zeidler, Jörg Mahlich, Wolfgang Greiner, Stephan Heres

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Treatment with antipsychotic medication is an important element of relapse prevention in the management of schizophrenia, and can reduce inpatient stays. Recently, the long-acting atypical antipsychotic paliperidone long-acting injectable (PLAI), a once-monthly LAI antipsychotic, was approved for treatment of schizophrenia in Germany.

Objective

To estimate, based on a previously published model, the cost effectiveness of PLAI compared with other common antipsychotic treatment strategies in patients diagnosed with schizophrenia in Germany.

Methods

A Markov decision analytic model was adapted to the German healthcare system. The model considers the cost effectiveness for PLAI as a maintenance treatment for patients with schizophrenia from the payer perspective. The patients transition between eight health states on a monthly basis over a 5-year time horizon. As therapeutic strategies, PLAI, quetiapine, risperidone long-acting injections (RLAI), oral olanzapine, oral risperidone, zuclopenthixol decanoate, olanzapine long-acting injections (OLAI), oral typical and oral atypical were compared. Probability of relapse, level of adherence, side effects and treatment discontinuation were derived from the Swedish original model. Input factors regarding resource use and costs were estimated and adjusted for the German healthcare system. A probabilistic sensitivity analyses (PSA) using cost-effectiveness scatter plots was performed to visualize the robustness of the results.

Results

In base-case scenario, PLAI is superior to RLAI in gained quality-adjusted life-years (QALYs) and avoided relapses. Relative to all other treatment strategies, PLAI is more effective with regard to gained QALYs and avoided relapses but results in higher treatment costs over a 5-year horizon in base-case scenario. The results were tested in PSA. If a cost-effectiveness threshold of €30,000 is assumed, for example, PLAI can be considered to be cost effective compared with RLAI in about 92.5 % of cases regarding gained QALYs, and in 78.6 % of cases regarding avoided relapse. Compared with OLAI, in about 94.4 % of cases regarding gained QALYs and in 99.9 % of cases regarding avoided relapse, cost effectiveness can be considered. Comparing PLAI and zuclopenthixol decanoate, cost effectiveness can be assumed in about 90.4 % of cases regarding gained QALYs, and in all cases regarding avoided relapse.

Conclusions

PLAI dominates RLAI and compared with the other treatment strategies PLAI has shown to be more effective but results in higher costs in base-case scenario.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Robert Koch-Institut. Gesundheitsberichterstattung des Bundes: Heft 50—Schizophrenie (The Federal Health Monitoring System: issue 50—schizophrenia). Berlin: Robert Koch-Institut; 2010.
2.
Rössler W, Salize J, Knapp M. Die Kosten der Schizophrenie (The costs of schizophrenia). Fortschr Neurol Psychiatr. 1998;66(11):496–504.PubMedCrossRef
3.
4.
Von der Schulenburg JM, Uber A, Höffler J, et al. Untersuchungen zu den direkten und indirekten Kosten der Schizophrenie (Studies on direct and indirect costs of schizophrenia). Gesundheitsökonomie & Qualitätsmanagement. 1998;3:81–7.
5.
Kissling W, Höffler J, Seemann U, et al. Die direkten und indirekten Kosten der Schizophrenie (Direct and indirect costs of schizophrenia). Fortschr Neurol Psychiatr. 1999;67(1):29–36.PubMedCrossRef
6.
Roick C, Killian R, Reinhold K, et al. Die indirekten Kosten schizophrener Psychosen (Indirect costs of schizophrenia). Gesundheitsökonomie & Qualitätsmanagement. 2001;6(2):36–43.CrossRef
7.
Konnopka A, Klingberg S, Wittorf A, et al. Die Kosten der Schizophrenie in Deutschland: Ein systematischer Literaturüberblick (The cost of schizophrenia in Germany: a systematic review of the literature). Psychiatr Prax. 2009;36(5):211–8.PubMedCrossRef
8.
Klosterkötter J. Indizierte Prävention schizophrener Erkrankungen (Indicated prevention of schizophrenia). Dtsch Arztebl. 2008;105(30):A10532.
9.
Kilian R, Roick C, Matschinger H, et al. Die Analyse von Kostenstrukturen im Bereich der Schizophreniebehandlung mit einem standardisierten Instrumentarium (The analysis of the cost structures of the treatment of schizophrenia by means of standardized assessment instruments). Psychiatr Prax. 2001;28(Suppl. 2):S102–8.PubMedCrossRef
10.
Salize HJ, Rössler W, Reinhard I. Kostenermittlung in einem fragmentierten psychiatrischen Versorgungssystem (Cost assessment in a fragmented psychiatric treatment system). Gesundheitswesen. 1996;Suppl. 1:10–7.
11.
Osterheider M, Franken-Hiep K, Horn R. Gesamtkrankenkosten der Schizophrenie und monetäre Bewertung einer Rezidivprophylaxe am Beispiel eines Standard-Depot-Neuroleptikums (Flupentixoldecanoat) (Total illness costs of schizophrenia and monetary evaluation of prevention of recurrence exemplified by a standard depot neuroleptic (flupenthixol decanoate)). Psychiatr Prax. 1998;25(1):38–43.PubMed
12.
Zeidler J, Slawik L, Fleischmann J, et al. Impact and costs of hospitalisation in schizophrenia [abstract]. Value Health. 2010;13(7):A449.CrossRef
13.
Rummel-Kluge C, Schuster T, Peters S, et al. Partial compliance with antipsychotic medication is common in patients with schizophrenia. Aust N Z J Psychiatry. 2008;42(5):382–8.PubMedCrossRef
14.
Marder SR. Overview of partial compliance. J Clin Psychiatry. 2003;64(Suppl. 16):3–9.PubMed
15.
Acosta FJ, Bosch E, Sarmiento G, et al. Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr Res. 2009;107(2):213–7.PubMedCrossRef
16.
Willis M, Svensson M, Löthgren M, et al. The impact of schizophrenia-related hospital utilization and cost of switching to long-acting risperidone injections in Sweden. Eur J Health Econ. 2010;11(6):585–94.PubMedCrossRef
17.
Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–9.PubMedCrossRef
18.
Grimaldi-Bensouda L, Rouillon F, Astruc B, et al. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res. 2012;134(2–3):187–94.PubMedCrossRef
19.
Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia—a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1–3):83–92.PubMedCrossRef
20.
Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 2009;24(5):287–96.PubMedCrossRef
21.
Olivares JM, Rodriguez-Martinez A, Burón JA, et al. Cost-effectiveness analysis of switching antipsychotic medication to longacting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy. 2008;6(1):41–53.PubMedCrossRef
22.
Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label. Randomized clinical trial. Neuropsychopharmacology. 2010;35(12):2367–77.PubMedCentralPubMedCrossRef
23.
Spill B, Konoppa S, Kissling W, et al. Long-term observation of patients successfully switched to risperidone long-acting injectable: a retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. Int J Psychiatry Clin Pract. 2010;14:53–62.CrossRef
24.
Laux G, Heeg B, van Hout B, et al. Costs and effects or long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. PharmacoEconomics. 2005;23(Suppl. 1):49–61.PubMed
25.
Einarson T, Geitona M, Chaidemenos A, et al. Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. Ann Gen Psychiatry. 2012;11:18.PubMedCentralPubMedCrossRef
26.
27.
Mehnert A, Nicholl D, Pudas H, et al. Cost-effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Schweden. J Med Econ. 2012;15(5):844–61.PubMedCrossRef
28.
Kim B, Lee TJ, Woo JM, et al. Cost-utility analysis of paliperidone Palmitat long acting injection (PLAI) vs oral atypical antipsychotics in non-adherent schizophrenia patients. Value Health. 2011;14(7):A294.CrossRef
29.
Ahn J, McCombs JS, Jung C, et al. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health. 2008;11:48–56.PubMedCrossRef
30.
Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115:260–7.PubMedCrossRef
31.
Sim K, Su A, Ungvari GS, et al. Depot antipsychotic use in schizophrenia: an East Asian perspective. Hum Psychopharmacol. 2004;19:103–9.PubMedCrossRef
32.
Edwards NC, Muser E, Doshi D, et al. The threshold rate of oral atypical anti-psychotic adherence at which paliperidone Palmitat is cost saving. J Med Econ. 2012;15(4):1–12.CrossRef
33.
Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes. 2008;6:105.PubMedCentralPubMedCrossRef
34.
35.
Prenzler A, Zeidler J, Braun S, et al. Bewertung von Ressourcen im Gesundheitswesen aus der Perspektive der deutschen Sozialversicherung (Assessment of health care resources from the viewpoint of the German social insurance system). PharmacoEconomics. 2010;8(1):47–66.
36.
Braun S, Prenzler A, Mittendorf T, et al. Bewertung von Ressourcenverbräuchen im deutschen Gesundheitswesen aus Sicht der Gesetzlichen Krankenversicherung (Appraisal of resource use in the German health-care system from the perspective of the statutory health insurance). Gesundheitswesen. 2009;71:19–23.PubMedCrossRef
37.
38.
39.
40.
Braun S, Zeidler J, Mittendorf T, et al. Kosteneffektivität von Quetiapin und Haloperidol bei Patienten mit partiell therapieresistenter Schizophrenie (Cost-effectiveness analysis of quetiapine and haloperidol for partial responders in schizophrenia). PharmacoEconomics. 2010;8(1):21–9.
41.
42.
43.
44.
Bestehorn M, Tischer B, Glaser P, et al. Repräsentative Studie zur Verteilung schizophrener Patienten auf medizinische Versorgungseinrichtungen in Deutschland (Representative Study on the Distribution of Schizophrenia Patients to Medical Health Care Institutions in Germany). Fortschr Neurol Psychiatr Grenzgeb. 1999;67:487–92.CrossRef
45.
Fritze J. Entgeltsystem für psychiatrische und psychosomatische Einrichtungen (Remuneration System for psychiatric and psychosomatic facilities). In: Klauber J, Geraedts M, Friedrich J, editors. Krankenhaus-Report 2010. Stuttgart: Schattauer; 2009. p. 181–208.
46.
47.
Hong J, Windmeijer F, Novick D, et al. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Progr Neuropsychopharmacol Biol Psychiatry. 2009;33(5):835–41.CrossRef
48.
Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57(Suppl 9):5–9.PubMed
49.
Schützwohl M, Glöckner M, Matthes C, et al. The burden on relatives of acute mentally ill within the first four weeks of day hospital and inpatient treatment. Results from a randomized controlled trial. Psychiatr Prax. 2005;32(6):281–8.PubMedCrossRef
50.
Schmid R, Neuner T, Cording C, et al. Schizophrenic patients’ quality of life-association with coping, locus of control, subjective well-being, satisfaction and patient-judged caregiver burden. Psychiatr Prax. 2006;33(7):337–43.PubMedCrossRef
51.
Emsley R, Nuamah I, Hough D, et al. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res. 2012;138(1):29–34.PubMedCrossRef
52.
Heres S, Schmitz FS, Leucht S, et al. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007;22(5):275–82.PubMedCrossRef
53.
Patel MX, de Zoysa N, Bernadt M, et al. Are depot antipsychotics more coercive than tablets? The patient’s perspective. J Psychopharmacol. 2010;24(10):1483–9.PubMedCrossRef
54.
Patel MX, De Zoysa N, Bernadt M, et al. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol. 2009;23(7):789–96.PubMedCrossRef
55.
Frey S, Linder R, Juckel G, et al. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data. Eur J Health Econ. 2013. doi:10.​1007/​s10198-013-0460-9.PubMed
56.
Stargardt T, Edel MA, Ebert A, et al. Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany. J Clin Psychopharmacol. 2012;32(5):602–7.PubMedCrossRef
Metadaten
Titel
Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
verfasst von
Jan Zeidler
Jörg Mahlich
Wolfgang Greiner
Stephan Heres
Publikationsdatum
01.10.2013
Verlag
Springer International Publishing
Erschienen in
Applied Health Economics and Health Policy / Ausgabe 5/2013
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-013-0050-0

Weitere Artikel der Ausgabe 5/2013

Applied Health Economics and Health Policy 5/2013 Zur Ausgabe

Current Opinion

Generic Medicines: Solutions for a Sustainable Drug Market?

Original Research Article

Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US

Original Research Article

Preferences for Colorectal Cancer Screening Techniques and Intention to Attend: a Multi-Criteria Decision Analysis

Original Research Article

Economic Evaluation of Cardio inCode®, a Clinical-Genetic Function for Coronary Heart Disease Risk Assessment

Original Research Article

Private Expenditures on Brand Name Prescription Drugs after Generic Entry

Systematic Review

Systematic Review of Drug Administration Costs and Implications for Biopharmaceutical Manufacturing